COVID-19 in pediatric patients: a case series from the Bronx, NY

Einat Blumfield1, Terry L Levin2

  • 1Department of Radiology, Division of Pediatric Radiology, Montefiore Medical Center, 111 E. 210th St., Bronx, NY, 10467, USA. eblumfie@montefiore.org.

Pediatric Radiology
|July 31, 2020
PubMed

Insights

Critically ill children with COVID-19 can develop myocarditis or pulmonary disease. Multisystemic inflammatory syndrome in children (MIS-C) presented with myocarditis, while adolescents showed significant lung opacities.

Area of Science:

  • Pediatric critical care medicine
  • Infectious diseases
  • Radiology

Background:

  • Coronavirus disease 2019 (COVID-19) predominantly impacts adults, with children experiencing a lower incidence.
  • Understanding the clinical presentation and outcomes of severe COVID-19 in pediatric populations is crucial.

Purpose of the Study:

  • To describe the clinical characteristics and radiographic findings of critically ill children with COVID-19.
  • To differentiate presentations of COVID-19 in younger children versus adolescents.

Main Methods:

  • Retrospective review of medical records for children admitted with COVID-19 between February 25 and May 1, 2020.
  • Analysis of patient demographics, symptoms, comorbidities, respiratory support needs, acute myocardial injury, and chest radiograph findings.

Main Results:

  • Nineteen children (2 months–18 years) were included; 18 tested positive for COVID-19.
  • Fever, cough, and respiratory distress were common symptoms. Comorbidities were present in 63% of patients.
  • Five patients developed acute myocarditis, often associated with multisystemic inflammatory syndrome in children (MIS-C) in younger children. Adolescents predominantly showed radiographic evidence of lung disease.

Conclusions:

  • Myocarditis without pulmonary disease can be a manifestation of MIS-C in young children.
  • Pulmonary disease, characterized by perihilar and basilar opacities, was the dominant radiographic finding in adolescents with COVID-19.
  • COVID-19 presents differently in pediatric age groups, necessitating tailored diagnostic and management approaches.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...